Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on Sangamo Therapeutics in a report on Sunday, July 28th. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $2.67.

Sangamo Therapeutics Stock Up 32.5 %

Shares of Sangamo Therapeutics stock opened at $1.21 on Tuesday. Sangamo Therapeutics has a 12-month low of $0.29 and a 12-month high of $1.48. The company has a market capitalization of $251.95 million, a price-to-earnings ratio of -0.88 and a beta of 1.23. The firm’s 50-day moving average price is $0.86 and its two-hundred day moving average price is $0.66.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. On average, sell-side analysts expect that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Sangamo Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vontobel Holding Ltd. boosted its holdings in shares of Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 241,440 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Sangamo Therapeutics during the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Sangamo Therapeutics during the second quarter worth about $89,000. Marshall Wace LLP increased its stake in shares of Sangamo Therapeutics by 56.3% in the second quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 207,476 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after buying an additional 1,528,600 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.